The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.

MLA

Yang, Hui, et al. “The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.” Frontiers in Oncology, vol. 11, Nov. 2021, pp. 1–8. EBSCOhost, https://doi.org/10.3389/fonc.2021.707041.

APA

Yang, H., Wang, K., Li, B., Li, S., Li, Y., & Yuan, L. (2021). The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy. Frontiers in Oncology, 11, 1–8. https://doi.org/10.3389/fonc.2021.707041

Chicago

Yang, Hui, Kunlun Wang, Bingxu Li, Shenglei Li, Yan Li, and Ling Yuan. 2021. “The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.” Frontiers in Oncology 11 (November): 1–8. doi:10.3389/fonc.2021.707041.